Jefferies and Deutsche Bank Lower Price Targets on Kenvue (KVUE)

Kenvue Inc. (NYSE:KVUE) is one of the 10 Stocks Under $20 to Buy According to Analysts. On October 27, Jefferies reduced its price target on Kenvue Inc. (NYSE:KVUE) from $25 to $23 and kept a Buy rating.

Jefferies noted that retail trends are showing signs of weakness. The research firm highlighted a 1.5% drop, which represents a 100 basis point reduction quarter-over-quarter. The company is also facing legal challenges in the United Kingdom related to allegations that its talc products cause cancer.

According to Jefferies, the lower price target accounts for “lower visibility into turnaround timing, given liability risk.” Despite this, the research firm believes Kenvue Inc.’s (NYSE:KVUE) guidance for 2025 will remain intact. The firm also suggested that updates related to a new permanent CEO and the company’s strategic review could prove to be more important to investors right now. Jefferies expects to see these announcements soon.

Previously, on October 24, Deutsche Bank had also reduced its price target on Kenvue Inc. (NYSE:KVUE) from $20 to $18 and maintained a Hold rating.

Kenvue Inc. (NYSE:KVUE) is a global consumer health company. The company’s brands include iconic names like Aveeno, BAND-AID, Johnson’s, Listerine, Neutrogena, and Tylenol.

While we acknowledge the potential of KVUE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best American AI Stocks to Buy According to Analysts and 11 Dirt Cheap Stocks to Buy According to Analysts.

Disclosure: None. This article is originally published at Insider Monkey.